期刊
FAMILIAL CANCER
卷 10, 期 2, 页码 193-197出版社
SPRINGER
DOI: 10.1007/s10689-011-9418-1
关键词
Ovarian cancer; BRCA1; BRCA2; Genetic testing; Genetic counseling; Recurrent cancer; End of life issues
资金
- NCI NIH HHS [P30 CA016672] Funding Source: Medline
10-15% of invasive epithelial ovarian cancer is attributable to hereditary breast and ovarian cancer. The identification of BRCA1/BRCA2 mutations in women with ovarian cancer allows for accurate predictive genetic testing of their at-risk relatives, who can then avail themselves of early detection and risk reduction strategies. In the case of women with recurrent progressive ovarian cancer, the window of opportunity for genetic testing can be particularly limited. Here we describe our perspective on providing genetic counseling during these patients' end of life care, incorporating two illustrative examples from our clinical practice. While these situations pose unique challenges, they also present a significant opportunity to benefit the patient and her family. Further attention and research should be directed towards provision of genetic counseling and testing during end of life care.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据